Andrew Berchuck, MD

Related Content

Services

• Gynecologic Cancer
• Gynecology

Department / Division:
Obstetrics and Gynecology / Gynecologic Oncology

Address:
DUMC 3079
Durham, NC 27710

Appointment Telephone:
(919) 684-3765

Office Telephone:
(919) 684-3765

Fax Telephone:
(919) 684-8719

• M.D., Case Western Reserve University, Ohio, 1980

• OB/GYN, Case Western Reserve University, Ohio, 1980-1984

• Gynecologic Oncology, Sloan-Kettering Cancer Center, New York, 1985-1987

Clinical Interests:
Gynecologic malignancies, premalignant diseases of the cervix and vagina, radical pelvic surgery, chemotherapy, radiation therapy, reconstructive pelvic surgery, laser surgery, complicated gynecologic surgery, hereditary ovarian and endometrial cancer, minimally invasive laparoscopic surgery

Research Interests:
Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the F. Bayard Carter Distinguished Professorship.  He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers.  This includes minimally invasive laparoscopic surgical approaches.  He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium.  He has published over 200 peer-reviewed papers in these areas.  The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) using microarrays to define molecular signatures that are predictive of clinical phenotypes and response to targeted biological therapies.  Twenty-five fellows and residents have worked in his lab, several of whom are now funded investigators.  His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncologists and the International Gynecologic Cancer Society.  Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006.  He has served as editor of several books in the field including: Biology of Female Cancers, Ovarian Cancer and Endometrial Cancer.  Dr. Berchuck also has a major commitment to national activities, and was elected President of the Society of Gynecologic Oncologists for 2007-2008.  Finally, he serves as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (www.ocrf.org) in New York.

Representative Publications:
Havrilesky L, Darcy M, Hamdan H, Priore RL, Leon J, Bell J, Berchuck A, . Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2003 Oct 15;21(20):3814-25. (2003) Abstract

Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, Lancaster J, Nevins JR. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006 Nov;12(11):1294-300. (2006) Abstract

Guillem JG, Wood WC, Moley JF, Berchuck A, Karlan BY, Mutch DG, Gagel RF, Weitzel J, Morrow M, Weber BL, Giardiello F, Rodriguez-Bigas MA, Church J, Gruber S, Offit K, , . ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol. 2006 Oct 1;24(28):4642-60. (2006) Abstract

Jewell E, Secord AA, Brotherton T, Berchuck A. Use of trastuzumab in the treatment of metastatic endometrial cancer. Int J Gynecol Cancer. 2006 May-Jun;16(3):1370-3. (2006) Abstract

Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA Jr, Marks JR, Dressman HK, West M, Nevins JR. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006 Jan 19;439(7074):353-7. (2006) Abstract

Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005 Jun 1;23(16):3668-75. (2005) Abstract

Spillman MA, Lacy J, Murphy SK, Whitaker RS, Grace L, Teaberry V, Marks JR, Berchuck A. Regulation of the metastasis suppressor gene MKK4 in ovarian cancer. Gynecol Oncol. 2007 Feb 2. (2007) Abstract

Spillman MA, Schildkraut JM, Halabi S, Moorman P, Calingaert B, Bentley RC, Marks JR, Murphy S, Berchuck A. Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. Gynecol Oncol. 2005 May;97(2):543-9. (2005) Abstract

Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol. 2007 Feb 10;25(5):517-25. (2007) Abstract

Berchuck A, Schildkraut JM, Wenham RM, Calingaert B, Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM, Kelemen L, Spurdle AB, Marks J, Chenevix-Trench G. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2141-7. (2004) Abstract

Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005 May 15;11(10):3686-96. (2005) Abstract

Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A. Analgesic drug use and risk of ovarian cancer. Epidemiology. 2006 Jan;17(1):104-7. (2006) Abstract